294 related articles for article (PubMed ID: 32437738)
61. Liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis.
Bourget P; Amin A; Chandesris MO; Vidal F; Merlette C; Hirsch I; Cabaret L; Carvalhosa A; Mogenet A; Frenzel L; Damaj G; Lortholary O; Hermine O
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 944():175-81. PubMed ID: 24316764
[TBL] [Abstract][Full Text] [Related]
62. Advanced systemic mastocytosis-Revised classification, new drugs and how we treat.
Pardanani A; Reichard K; Tefferi A
Br J Haematol; 2024 Feb; 204(2):402-414. PubMed ID: 38054381
[TBL] [Abstract][Full Text] [Related]
63. Criteria for the Regression of Pediatric Mastocytosis: A Long-Term Follow-Up.
Polivka L; Rossignol J; Neuraz A; Condé D; Agopian J; Méni C; Garcelon N; Dubreuil P; Maouche-Chrétien L; Hadj-Rabia S; Hermine O; Bodemer C
J Allergy Clin Immunol Pract; 2021 Apr; 9(4):1695-1704.e5. PubMed ID: 33338682
[TBL] [Abstract][Full Text] [Related]
64. Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
Lyberg K; Ali HA; Grootens J; Kjellander M; Tirfing M; Arock M; Hägglund H; Nilsson G; Ungerstedt J
Oncotarget; 2017 Feb; 8(6):9647-9659. PubMed ID: 28038453
[TBL] [Abstract][Full Text] [Related]
65. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340
[TBL] [Abstract][Full Text] [Related]
66. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392
[TBL] [Abstract][Full Text] [Related]
67. Midostaurin in Advanced Systemic Mastocytosis.
Chandesris MO; Damaj G; Canioni D; Brouzes C; Lhermitte L; Hanssens K; Frenzel L; Cherquaoui Z; Durieu I; Durupt S; Gyan E; Beyne-Rauzy O; Launay D; Faure C; Hamidou M; Besnard S; Diouf M; Schiffmann A; Niault M; Jeandel PY; Ranta D; Gressin R; Chantepie S; Barete S; Dubreuil P; Bourget P; Lortholary O; Hermine O;
N Engl J Med; 2016 Jun; 374(26):2605-7. PubMed ID: 27355555
[No Abstract] [Full Text] [Related]
68. A Granular Approach to a Patient with Diarrhea and Flushing.
Gremida A; Mir F; McCarthy D
Dig Dis Sci; 2019 Jul; 64(7):1792-1797. PubMed ID: 31111279
[No Abstract] [Full Text] [Related]
69. Development and validation of the mastocytosis quality of life questionnaire: MC-QoL.
Siebenhaar F; von Tschirnhaus E; Hartmann K; Rabenhorst A; Staubach P; Peveling-Oberhag A; Wagner N; Martus P; Carter MC; Metcalfe DD; Church MK; Maurer M; Weller K
Allergy; 2016 Jun; 71(6):869-77. PubMed ID: 26797792
[TBL] [Abstract][Full Text] [Related]
70. The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.
Jawhar M; Schwaab J; Meggendorfer M; Naumann N; Horny HP; Sotlar K; Haferlach T; Schmitt K; Fabarius A; Valent P; Hofmann WK; Cross NCP; Metzgeroth G; Reiter A
Haematologica; 2017 Jun; 102(6):1035-1043. PubMed ID: 28255023
[TBL] [Abstract][Full Text] [Related]
71. Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.
Peter B; Bibi S; Eisenwort G; Wingelhofer B; Berger D; Stefanzl G; Blatt K; Herrmann H; Hadzijusufovic E; Hoermann G; Hoffmann T; Schwaab J; Jawhar M; Willmann M; Sperr WR; Zuber J; Sotlar K; Horny HP; Moriggl R; Reiter A; Arock M; Valent P
Leukemia; 2018 Apr; 32(4):1016-1022. PubMed ID: 29249817
[TBL] [Abstract][Full Text] [Related]
72. Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study.
Hochhaus A; Baccarani M; Giles FJ; le Coutre PD; Müller MC; Reiter A; Santanastasio H; Leung M; Novick S; Kantarjian HM
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2047-60. PubMed ID: 26002753
[TBL] [Abstract][Full Text] [Related]
73. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis.
Reiter A; Schwaab J; DeAngelo DJ; Gotlib J; Deininger MW; Pettit KM; Alvarez-Twose I; Vannucchi AM; Panse J; Platzbecker U; Hermine O; Dybedal I; Lin HM; Rylova SN; Ehlert K; Dimitrijević S; Radia DH
Blood Adv; 2022 Nov; 6(21):5750-5762. PubMed ID: 35640224
[TBL] [Abstract][Full Text] [Related]
74. Importance of Adequate Diagnostic Workup for Correct Diagnosis of Advanced Systemic Mastocytosis.
Schwaab J; Cabral do O Hartmann N; Naumann N; Jawhar M; Weiß C; Metzgeroth G; Schmid A; Lübke J; Reiter L; Fabarius A; Cross NCP; Sotlar K; Valent P; Kluin-Nelemans HC; Hofmann WK; Horny HP; Panse J; Reiter A
J Allergy Clin Immunol Pract; 2020 Oct; 8(9):3121-3127.e1. PubMed ID: 32422371
[TBL] [Abstract][Full Text] [Related]
75. Magnetic resonance imaging reveals distinct bone marrow patterns in indolent and advanced systemic mastocytosis.
Riffel P; Jawhar M; Gawlik K; Schwaab J; Michaely HJ; Metzgeroth G; Hofmann WK; Schoenberg SO; Reiter A
Ann Hematol; 2019 Dec; 98(12):2693-2701. PubMed ID: 31686155
[TBL] [Abstract][Full Text] [Related]
76. [Mastocytosis-a frequently unrecognized disease].
Muñoz M; Siebenhaar F
Dermatologie (Heidelb); 2024 Jan; 75(1):75-86. PubMed ID: 38085334
[TBL] [Abstract][Full Text] [Related]
77. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2015 Mar; 90(3):250-62. PubMed ID: 25688753
[TBL] [Abstract][Full Text] [Related]
78. Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis.
Quintás-Cardama A; Sever M; Cortes J; Kantarjian H; Verstovsek S
Leuk Lymphoma; 2013 Sep; 54(9):1959-64. PubMed ID: 23278641
[TBL] [Abstract][Full Text] [Related]
79. Tyrosine Kinase Inhibitors in Non-advanced Systemic Mastocytosis.
Akin C
Immunol Allergy Clin North Am; 2023 Nov; 43(4):743-750. PubMed ID: 37758410
[TBL] [Abstract][Full Text] [Related]
80. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2013 Aug; 91(2):106-11. PubMed ID: 23621866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
